To all the OWCP bashers let's recap:
OWCP will be the cannabis stock of 2017:
Market Value: With a low $96 million Market Cap (as of January 18, 2017), they’re have tons of room for growth. We feel they’re so undervalued because they are still pre-revenue. But, that changes in Quarter 2 of 2017. When you consider AstraZeneca auctioned off their “troubled psoriasis drug” for $445 million in 2015 — isn’t it fair to say an assumed-to-be superior psoriasis drug is worth at least that? Then consider the patents mentioned in reason #9 below.
OTC QB, not Pink Sheets. Most people who are making an investment (not flipping) are usually uncomfortable with Pink Sheet stocks. To see the list of requirements and understand the line of thinking here, check out OTCmarkets.com.
Share Structure: The outstanding share count, verified by OTCmarkets.com, is 139,255,474 as of January 1, 2017. There are a couple of cannabis sector stocks with far higher Market Values trading on the Pink Sheets with 2.3 BILLION outstanding shares, despite having little or no revenue.
No Toxic Debt: Again, unlike many Pink Sheet companies — OWCP, as announced in an 8-K on October 3, 2016, has no convertible notes whatsoever. Instead, they have non-interest bearing financing.
Distribution & Manufacturing Deals: Back in March 2016, they announced a manufacturing deal with Emilia Cosmetics, one of Israel’s largest private label cosmetics companies. In September 2016, OWCP got a $300,000 deal with MedMar for distribution in the USA. Then, in November 2016, OWCP announced a $300,000 deal with Michepro to promote, market, sell, and distribute products throughout Europe for a 25% cut.
Real Doctor(s): Dr. Yehuda Baruch, MD is a real doctor who was the head of the Israeli Medical Use of Cannabis Programme from 2003 – 2012. Read more from the Medical Cannabis Conference website.
Products to Launch: The January 12th 8-K announced a new research agreement with the largest hospital in Israel after IRB approval. You can see on ClinicalTrails.gov that there really is an ongoing study. On October 11th, 2016, they announced the Final Phase for Testing of their Psoriasis Cream. Then, on October 20th, 2016, they announced the completed development of a Medical Cannabis Sublingual Tablet — a smoke-free alternative.
Expert Advisors: OWCP has brilliant industry advisors like Jeffrey Friedland, who wrote the book “Marijuana: The World’s Most Misunderstood Plant“. Mr. Friedland continues to make his rounds doing speaking engagements and expert panels at various Cannabis / Medical Marijuana conferences. Check his website for upcoming events — www.jeffreyfriedland.com.
Provisional Patents: OWCP has EIGHT provisional patents with the United States Patent and Regulatory Office (USPTO), all related to its line of activity related to cannabis-based medical products.
Acquisition Possibility: TEVA, a 115 year old Israel-based pharmaceutical company with over $20 billion in revenue, supposedly discussed buying OWCP’s patents. (I say ‘supposedly’ because there was never a press release, just a report from ‘The Marker‘ (screenshot of article translated to English with Google) and ‘The Jewish Press’ – both out of Israel.) Even if an official offer was never presented, TEVA themselves have acquired nearly a dozen companies in the last decade. In addition to TEVA, there are many ‘Big Pharma’ companies who have publicly announced they’re looking for new acquisitions.
Comparison: Simply compare GWPH to OWCP. That’s exactly what OWCP can become later this year. Want to be conservative? If OWCP grows to 1/3rd of GWPH’s Market Value, they’ll be trading around $7.18/share. The reason we feel this is realistic? GWPH has only one FDA approved product thus far. OWCP could easily have two (or more) out by the end of 2017. In all honesty, it seems like it’s only a matter of time until OWCP surpasses GWPH’s Market Value.
OWCP will be the cannabis stock of 2017:
Market Value: With a low $96 million Market Cap (as of January 18, 2017), they’re have tons of room for growth. We feel they’re so undervalued because they are still pre-revenue. But, that changes in Quarter 2 of 2017. When you consider AstraZeneca auctioned off their “troubled psoriasis drug” for $445 million in 2015 — isn’t it fair to say an assumed-to-be superior psoriasis drug is worth at least that? Then consider the patents mentioned in reason #9 below.
OTC QB, not Pink Sheets. Most people who are making an investment (not flipping) are usually uncomfortable with Pink Sheet stocks. To see the list of requirements and understand the line of thinking here, check out OTCmarkets.com.
Share Structure: The outstanding share count, verified by OTCmarkets.com, is 139,255,474 as of January 1, 2017. There are a couple of cannabis sector stocks with far higher Market Values trading on the Pink Sheets with 2.3 BILLION outstanding shares, despite having little or no revenue.
No Toxic Debt: Again, unlike many Pink Sheet companies — OWCP, as announced in an 8-K on October 3, 2016, has no convertible notes whatsoever. Instead, they have non-interest bearing financing.
Distribution & Manufacturing Deals: Back in March 2016, they announced a manufacturing deal with Emilia Cosmetics, one of Israel’s largest private label cosmetics companies. In September 2016, OWCP got a $300,000 deal with MedMar for distribution in the USA. Then, in November 2016, OWCP announced a $300,000 deal with Michepro to promote, market, sell, and distribute products throughout Europe for a 25% cut.
Real Doctor(s): Dr. Yehuda Baruch, MD is a real doctor who was the head of the Israeli Medical Use of Cannabis Programme from 2003 – 2012. Read more from the Medical Cannabis Conference website.
Products to Launch: The January 12th 8-K announced a new research agreement with the largest hospital in Israel after IRB approval. You can see on ClinicalTrails.gov that there really is an ongoing study. On October 11th, 2016, they announced the Final Phase for Testing of their Psoriasis Cream. Then, on October 20th, 2016, they announced the completed development of a Medical Cannabis Sublingual Tablet — a smoke-free alternative.
Expert Advisors: OWCP has brilliant industry advisors like Jeffrey Friedland, who wrote the book “Marijuana: The World’s Most Misunderstood Plant“. Mr. Friedland continues to make his rounds doing speaking engagements and expert panels at various Cannabis / Medical Marijuana conferences. Check his website for upcoming events — www.jeffreyfriedland.com.
Provisional Patents: OWCP has EIGHT provisional patents with the United States Patent and Regulatory Office (USPTO), all related to its line of activity related to cannabis-based medical products.
Acquisition Possibility: TEVA, a 115 year old Israel-based pharmaceutical company with over $20 billion in revenue, supposedly discussed buying OWCP’s patents. (I say ‘supposedly’ because there was never a press release, just a report from ‘The Marker‘ (screenshot of article translated to English with Google) and ‘The Jewish Press’ – both out of Israel.) Even if an official offer was never presented, TEVA themselves have acquired nearly a dozen companies in the last decade. In addition to TEVA, there are many ‘Big Pharma’ companies who have publicly announced they’re looking for new acquisitions.
Comparison: Simply compare GWPH to OWCP. That’s exactly what OWCP can become later this year. Want to be conservative? If OWCP grows to 1/3rd of GWPH’s Market Value, they’ll be trading around $7.18/share. The reason we feel this is realistic? GWPH has only one FDA approved product thus far. OWCP could easily have two (or more) out by the end of 2017. In all honesty, it seems like it’s only a matter of time until OWCP surpasses GWPH’s Market Value.
6
